97. 潰瘍性大腸炎 Ulcerative colitis Clinical trials / Disease details


臨床試験数 : 2,630 薬物数 : 1,459 - (DrugBank : 265) / 標的遺伝子数 : 144 - 標的パスウェイ数 : 202

  
3 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2018-004491-35-RO
(EUCTR)
30/01/202018/03/2022A study evaluating safety and efficacy of Itacitinib as treatment of moderate to severe ulcerative ColitisA Phase 2, Double-Blind, Dose-Ranging, Placebo-Controlled Study With Open-Label Extension to Evaluate the Safety and Efficacy of Itacitinib in Moderate to Severe Ulcerative Colitis Moderate to Severe Ulcerative Colitis
MedDRA version: 20.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Name: Itacitinib
Product Code: INCB039110
INN or Proposed INN: ITACITINIB ADIPATE
Other descriptive name: ITACITINIB ADIPATE
Incyte CorporationNULLNot RecruitingFemale: yes
Male: yes
206Phase 2United States;Czechia;Poland;Romania;Germany
2EUCTR2018-004491-35-PL
(EUCTR)
19/08/201903/07/2019A study evaluating safety and efficacy of Itacitinib as treatment of moderate to severe ulcerative ColitisA Phase 2, Double-Blind, Dose-Ranging, Placebo-Controlled Study With Open-Label Extension to Evaluate the Safety and Efficacy of Itacitinib in Moderate to Severe Ulcerative Colitis Moderate to Severe Ulcerative Colitis
MedDRA version: 20.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856 ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Name: Itacitinib
Product Code: INCB039110
INN or Proposed INN: ITACITINIB ADIPATE
Other descriptive name: ITACITINIB ADIPATE
Incyte CorporationNULLAuthorised-recruitment may be ongoing or finished Female: yes
Male: yes
206 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): noUnited States;Czech Republic;Poland;Romania;Germany
3NCT03627052
(ClinicalTrials.gov)
September 20, 20188/8/2018A Study to Evaluate the Safety and Efficacy of Itacitinib in Moderate to Severe Ulcerative ColitisA Phase 2, Double-Blind, Dose-Ranging, Placebo-Controlled Study With Open-Label Extension to Evaluate the Safety and Efficacy of Itacitinib in Moderate to Severe Ulcerative ColitisModerate to Severe Ulcerative ColitisDrug: Itacitinib;Drug: PlaceboIncyte CorporationNULLWithdrawn18 Years74 YearsAll0Phase 2United States